NDLI: Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets

Content Provider	Springer Nature Link
Author	Wu, Hao Sun, Yue Ye, Huihui Yang, Shi Lee, Stephanie L. Morenas, Antonio
Copyright Year	2015
Abstract	Anaplastic thyroid cancer (ATC) is a rare but aggressive malignancy of the thyroid. No effective treatment modalities are currently available. Targeted therapy against protein kinases showed promising results in preclinical studies. Our goal was to assess the mutational status of potential therapeutic targets, as well as the biomarker for immunotherapy in the clinical context. Using allele specific PCR, Sanger sequencing, fragment analysis and immunohistochemistry, we assessed BRAF, KRAS, EGFR mutations and protein overexpression of C-KIT and PDL1 in anaplastic thyroid cancer specimens. Results were compared to clinical information and patient outcome to assess the utility of these biomarkers. There were 13 patients in our study with a median overall survival of 19 weeks. Of the 13 ATC patients, 3 (23 %) had BRAF V600E mutation. C-KIT overexpression was found in 1 (8 %) patient who responded well to a tyrosine kinase inhibitor. PDL1 expression was seen in 3 (23 %) patients, none of them were surgical candidates due to unresectability and poor performance status. KRAS codon 12/13 and EGFR exon 18, 19, 20 and 21 were all wild type in our patients. Protein kinase inhibitors and immunotherapy may be useful adjuvant therapies for ATC.
Starting Page	695
Ending Page	701
Page Count	7
File Format	PDF
ISSN	12194956
Journal	Pathology & Oncology Research
Volume Number	21
Issue Number	3
e-ISSN	15322807
Language	English
Publisher	Springer Netherlands
Publisher Date	2015-01-15
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	Anaplastic thyroid cancer Targeted therapy PDL1 BRAF c-KIT Cancer Research Oncology Pathology Immunology Biomedicine general
Content Type	Text
Resource Type	Article
Subject	Cancer Research Pathology and Forensic Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib

Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer

Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

C-kit (CD117) Expression in Human Tumors and its Prognostic Value: An Immunohistochemical Analysis

Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management.

Molecular events as targets of anticancer drug therapy

GABA Receptor Expression in Benign and Malignant Thyroid Tumors

High Frequency of Genes’ Promoter Methylation, but Lack of BRAF V600E Mutation among Iranian Colorectal Cancer Patients

Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets

Similar Documents

Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib

Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer

Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

C-kit (CD117) Expression in Human Tumors and its Prognostic Value: An Immunohistochemical Analysis

Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management.

Molecular events as targets of anticancer drug therapy

GABA Receptor Expression in Benign and Malignant Thyroid Tumors

High Frequency of Genes’ Promoter Methylation, but Lack of BRAF V600E Mutation among Iranian Colorectal Cancer Patients

Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets